In 2020, Udi et al. [70] investigated the effect of a new hybrid inhibitor—dual cannabinoid receptor type 1 (CB1 receptor)/NOS2 antagonist—on the relief of obesity-induced chronic kidney disease (CKD). Here, NOS2 is linked to obesity due to melanocortin 4 receptor deficiency.